Predictive factors for the safe reduction of Methotrexate in the patients of rheumatoid arthritis under the golimumab treatment
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000038817
- Lead Sponsor
- ihon University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 458
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who had treated with 100mg GLM. The patients who have washout periods of GLM over twelve weeks. (To exclude the patients who have the possibility of treatment of other bDMARDs during washout periods) The patients who reduced the MTX dose but increased up to previous dose due to managing conditions. The patients who do not have the information about the disease activity (DAS28CRP) at baseline. The patients who refuted to join the study. The patients whom the researchers considered should not be included to the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method